Webcast ImageWebcast
Q4 2014 Incyte Corporation Earnings Conference Call (Live)
02/12/15 at 8:30 a.m. ET
Q4 2014 Incyte Corporation Earnings Conference Call
Thursday, February 12, 2015 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

The field of oncology is evolving rapidly and transforming how cancer is treated. We believe Incyte, rooted in rigorous science, is at the center of this transformation. Our pipeline includes innovative compounds in three major oncology areas: onco-inflammation, immuno-oncology and targeted therapies.

We believe our professional and financial resources, our experience and our prior success in bringing important new drugs to market put us in a strong position to make a difference in health care, improve the lives of patients and build sustainable value for our shareholders.


Recent News More >>
DateTitle 
January 27, 2015Incyte to Report Fourth Quarter/Year-End 2014 Financial Results on February 12
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 27, 2015-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its fourth quarter 2014 financial results conference call for 8:30 a.m. ET on Thursday, February 12, 2015. The schedule for the press release and conference call is as follows:         ... 
Printer Friendly Version
January 23, 2015Incyte Earns $25 Million Milestone as Jakavi® (ruxolitinib) Recommended for Approval in Europe for Polycythemia Vera
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 23, 2015-- Incyte Corporation (Nasdaq: INCY) today announced that it has earned a $25 million milestone payment from Novartis. This payment was triggered by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopting a positive opinion for Jakavi® (ruxolitinib) for the treatment of adult patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyu... 
Printer Friendly Version
January 09, 2015Incyte Board Appoints Two New Directors
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 9, 2015-- Incyte Corporation (Nasdaq: INCY) today announced the appointment of Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin Pharmaceutical Inc., and Paul J. Clancy, Executive Vice President, Finance and Chief Financial Officer of Biogen Idec Inc., as new Directors. The appointments are effective January 20, 2015. “The Incyte board welcomes Jean-Jacques and Paul as their extensive and re... 
Printer Friendly Version

2013 Annual Report
2013 Annual Report Download Documentation

2013 10-K

Notice To Readers: Incyte's press releases, presentations and printed remarks are included on this Web site for historical purposes only. The information contained in these documents and webcasts should be considered accurate only as of the date of the relevant document or presentation. This information may change over time; therefore, visitors to this Web site should not assume that the information contained in these documents or presentations remains accurate at a later time. We do not have any current intention, and expressly disclaim any obligation, to supplement, update or revise any of the information in these documents or presentations.


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.